A bio-healthcare companyGENEWEL

With human-centered technology to open happy future for mankind

Genewel delivers future and happiness to the world.


Since its establishment in 2000, Genewel has established an unrivaled position in the domestic biomaterials field by developing and launching the best brand wound dressing material “Medifoam” and anti-adhesion agent “Guardix” based on its outstanding technology.

Currently, the company is conducting R&D in areas such as wound dressing, anti-adhesion agents, tissue restoration materials, chronic wound treatment materials, and functional drugs, and is also making efforts to expand its influence into various fields such as high-functional medical devices.

In order to achieve the best brand power in Korea as well as in the world, we are continuously discovering talents and performing social contribution, and doing our best to become a company that faithfully fulfills its roles and responsibilities through ethical management based on transparency and fairness.

In addition, through various industry-academy cooperation and national projects, we are pioneering new possibilities and values, and are focusing on R&D to become a leading company in the field of biomaterials and as well as a global bio company.

  • C.E.OSang-Deok Han
  • Established 0n 2000.7.21.
  • Major ProductsWound dressing, anti-adhesives
  • Main Phone +82-31-8018-5500
  • Business Sites
    • Main Office. 37 62-gil, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do
      (5/6th fl., STAR TOWER, Sangdaewon-dong)
    • Hwasung . 281-2, Soltaesangdu-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea
Financial Status

Balance Sheet Unit : million KRW

Genewel 2023year Financial Status Table
FY 2021Y FY 2022Y FY 2023Y
Total Assets 38,149 42,260 43,533
Current assets 24,094 26,157 27,624
Non-current assets 14,055 16,102 15,909
Total Liabilities 8,224 7,492 5,258
Current liabilities 6,632 6,754 4,708
Non-current liabilities 1,592 737 551
Total Assets 29,926 34,768 38,275

Income Statement Unit : million KRW

Genewel 2023year Income Statement
FY 2021Y FY 2022Y FY 2023Y
Revenue 30,321 32,496 32,524
Operating profit 7,885 9,279 7,650
Net profit 6,102 7,762 6,827